Your Money at Work
JDRF has a bold plan for the future of type 1 diabetes (T1D) research in Canada. As better treatments unfold and the prospect of curing this disease rests on the horizon, we remain ever-committed to directing more resources to launch and sustain innovative research and clinical trials from coast-to-coast. Transforming Lives: Today and Tomorrow is our solution to accelerating diabetes breakthroughs in partnership with the community we support.
JDRF Research Funding Overview
Since its founding in 1970 (1974 in Canada), JDRF has funded more than $1.7 billion (U.S.) in T1D research and has dramatically advanced the T1D scientific frontier and the management of this disease. In FY2012 alone, JDRF provided more than $110 million (U.S.) for T1D research.
- As more JDRF programs move forward, the number of human or clinical studies has grown. In FY2012, JDRF supported over 50 clinical studies, including evaluations of new therapies, studies of the normal course of T1D, and others to collect specific T1D human samples.
A Look Back – Celebrating Success
Take a glimpse at some of the groundbreaking research innovations for T1D over the decades supported, in large part, by JDRF funding. The breadth of our achievements, and their impact on the fight to cure T1D, demonstrates why JDRF has been so successful in driving diabetes research for more than four decades.
The first test to measure long-term blood sugar levels – the haemoglobin A1C test – is developed with JDRF scientific backing. Thanks to this test, doctors can determine how well someone is controlling their diabetes over a period of months.
JDRF scientists established the relationship between low blood sugar and brain metabolism, helping to better understand and prevent the chronic effects of lower blood sugar on the brain.
JDRF researchers were the first to confirm that high blood sugar levels lead to increased risk of diabetic eye disease.
JDRF researchers led by Dr. James Shapiro at the University of Alberta unveiled the Edmonton Protocol for islet transplants, which uses less toxic immune-suppressing drugs and greatly improves transplant success rates.
The U.S. Food and Drug Administration approved a computer model of diabetes developed by JDRF researchers, helping to accelerate development of a working artificial pancreas and eliminating the need for animal testing.
A Look Forward – Where Are We Going?
To continue making a difference, JDRF has an ambitious plan for the future of T1D research in Canada. As better treatments unfold and the prospect of curing this disease rests on the horizon, we remain ever-committed to directing more resources to launch and sustain innovative research and clinical trials from coast-to-coast.
The largest campaign in JDRF’s history, Transforming Lives: Today and Tomorrow, is JDRF’s solution to help accelerate diabetes breakthroughs in partnership with the community we support.
Between 2010 and 2014, JDRF will invest $130 million to:
- Support top Canadian scientific research leading to a cure for T1D;
- Advance research into new treatment therapies that dramatically reduce the burden of T1D and its complications; and,
- Invest in JDRF Canadian Clinical Trial Network to help bring new technologies and treatments to market, and ensure that Canadians living with the disease are among the first to benefit from research.
Campaign donations may be directed to one or more of these priorities, with 80 per cent of funds expended supporting research, research-related education, and advocacy.
A testament to our community’s belief in our vision, JDRF Canada attracted $100 million to research through our “Research to Reality” campaign, which concluded in 2009. Our new campaign for $130 million will help advance and sustain basic and clinical diabetes research through to 2014.
Research Funding Facts
JDRF's research mission is to discover, develop, and deliver advances that cure, better treat, and prevent T1D. As the global leader in the fight against T1D, JDRF's research programs are comprehensive – addressing the hopes and dreams of every person with T1D for the best quality of life and a cure for this disease.